Funding for this research was provided by:
Gdański Uniwersytet Medyczny (grant number 01-10024 / 0006051 / 01 / 221 / 221 / 0 / 2024)
Article History
Accepted: 3 September 2024
First Online: 13 September 2024
Declarations
:
: Funding for this study was provided by Medical University of Gdańsk grant no. 01-10024/0006051/01/221/221/0/2024; the funder had no further role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; nor in the decision to submit the paper for publication.
: Michał Pastuszak: conceptualization, data curation, formal analysis, methodology, project administration, and writing—original draft; Wiesław Jerzy Cubała: conceptualization, formal analysis, methodology, supervision, and writing—review and editing; Aleksander Kwaśny: conceptualization, data curation, formal analysis, methodology, project administration, and writing—review & editing. All authors read and approved the final version.
: The data can be provided by the authors upon reasonable request.
: This study was registered in ClinicalTrials.gov under the identifiers NCT04226963 and NCT05565352 and the protocols for the study was approved by Ethic Research Committee of the Medical University of Gdańsk (NKBBN/172–674/2019 and NKBBN/172–447/2022). The study was performed in accordance with the standards of ethics outlined in the Declaration of Helsinki.
: All participants provided written informed consent prior to the enrollment in the study.
: Not applicable.
: Not applicable.
: Michał Pastuszak received research support from Beckley Psytech and MSD. Aleksander Kwaśny received research support from Beckley Psytech, GH Research, and MSD. Wiesław Jerzy Cubała has received grants from Acadia, Angelini, Celon, Cortexyme, GH Research, HMNC Brain Health, IntraCellular Therapies, Janssen, MSD, Novartis, and Otsuka. He has also received honoraria from Angelini, Celon, Janssen, Novartis, and Sanofi. He is a member of advisory boards in Angelini, Celon (terminated), Douglas Pharmaceuticals, Janssen, MSD, Novartis, and Sanofi.